东曜药业-B今日盘中大涨5.12%，引起了市场的广泛关注。
消息面上，公司于近期发布了截至2025年12月31日止的年度业绩报告。报告显示，尽管公司整体收益有所下降并录得亏损，但其CDMO（合同研发生产组织）业务表现亮眼，收入同比增长13%，已成为公司稳定的“压舱石”。
此外，公司在战略转型与国际化方面取得重要进展。自研产品朴欣汀®（贝伐珠单抗注射液）已在五个国家获得上市批准并完成首次海外订单发货，实现了从“注册获批”到“商业销售”的关键跨越。同时，公司已签约未完成订单达3.08亿元，同比增长61%，成功赋能全球首款EGFR ADC药物在中国获批，展现了在ADC等高壁垒领域的硬核实力。这些积极因素可能增强了市场对公司未来增长潜力的信心，从而推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.